🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Follicular Lymphoma and Marginal Zone Lymphoma

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia NCT05281809Phase 21 site📍 Pittsburgh John Lister · Tests: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946Phase 16 sites📍 Duarte📍 St Louis📍 Buffalo LTZ Therapeutics, Inc. · Tests: LTZ-301, LTZ-301, LTZ-301 SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma NCT04792502Phase 23 sites📍 New Haven📍 New Brunswick📍 Providence Brown University · Tests: Mosunetuzumab, Lenalidomide Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas NCT04883437Phase 21 site📍 Atlanta Emory University · Tests: Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment, Questionnaire Administration Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma NCT06442475Phase 21 site📍 Seattle University of Washington · Tests: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mosunetuzumab, Positron Emission Tomography CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319Phase 11 site📍 Boston Marcela V. Maus, M.D.,Ph.D. · Tests: CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader NCT05294731Phase 1, Phase 229 sites📍 Bengbu📍 Hefei📍 Beijing BeOne Medicines · Tests: Tacabrutideg Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. NCT04223765Phase 11 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: CAR.k.28, Fludarabine, Cyclophosphamide, Bendamustine Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT06859008Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography A Study of APG-3288 in Relapsed/Refractory Blood Cancers NCT07424833Phase 16 sites📍 Los Angeles📍 Jacksonville📍 Grand Rapids Ascentage Pharma Group Inc. · Tests: APG-3288 A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022Phase 162 sites📍 Duarte📍 San Francisco📍 Denver Nurix Therapeutics, Inc. · Tests: NX-5948 Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) NCT07225439Phase 12 sites📍 Cleveland📍 Cleveland Paolo Caimi, MD · Tests: Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma NCT06905509Phase 21 site📍 Sacramento University of California, Davis · Tests: Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine, Dexamethasone, Epcoritamab Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas NCT06350318Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Zanubrutinib, Rituximab Epco, Zanu, Ritux for R/R FL or MZL NCT06563596Phase 23 sites📍 Boston📍 New York📍 Columbus Reid Merryman, MD · Tests: Zanubrutinib, Rituximab, Epcoritamab AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737Phase 11 site📍 Palo Alto Stanford University · Tests: CD22CART Infusion HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL NCT06792825Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Tafasitamab, Rituximab, Lenalidomide CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520Phase 1, Phase 21 site📍 Milwaukee Medical College of Wisconsin · Tests: 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011n/a1 site📍 Freiburg im Breisgau iOMEDICO AG · Tests: Routine care as per site standard. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies NCT05780034Phase 19 sites📍 Denver📍 Sarasota📍 Chapel Hill Accutar Biotechnology Inc · Tests: AC676 Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905Phase 1, Phase 22 sites📍 Richmond📍 Nedlands ModeX Therapeutics, An OPKO Health Company · Tests: MDX2003 Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma NCT05326308n/a2 sites📍 Salzburg📍 Lübeck iOMEDICO AG · Tests: Zanubrutinib, Obinutuzumab Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies NCT04195633Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Filgrastim, Fludarabine A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma NCT06149286Phase 3171 sites📍 Los Angeles📍 Plantation📍 Indianapolis Regeneron Pharmaceuticals · Tests: Odronextamab, Lenalidomide, Rituximab MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) NCT04110301Phase 1, Phase 21 site📍 Beijing Beijing Mabworks Biotech Co., Ltd. · Tests: Recombinant Humanized Monoclonal Antibody MIL62 Injection, Lenalidomide
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy